1. Fecal microbiota transplantation decreases intestinal loads of multi-drug resistant Pseudomonas aeruginosa in murine carriers
- Author
-
Katharina Mrazek, Stefan Bereswill, and Markus M. Heimesaat
- Subjects
0301 basic medicine ,host-pathogen-interaction ,Host–pathogen interaction ,030106 microbiology ,lcsh:QR1-502 ,Multi-drug resistant Pseudomonas aeruginosa ,Endogeny ,medicine.disease_cause ,lcsh:Microbiology ,Microbiology ,03 medical and health sciences ,pro-inflammatory immune responses ,Medicine ,human microbiota associated mice ,In patient ,antibiotics-independent intervention strategies ,biology ,business.industry ,Pseudomonas aeruginosa ,fecal microbiota transplantation ,Fecal bacteriotherapy ,biology.organism_classification ,030104 developmental biology ,Carriage ,Multi drug resistant ,business ,Bacteria - Abstract
Intestinal carriage of multi-drug resistant (MDR) Gram-negative bacteria including Pseudomonas aeruginosa (Psae) constitutes a pivotal prerequisite for subsequent fatal endogenous infections in patients at risk. We here addressed whether fecal microbiota transplantation (FMT) could effectively combat MDR-Psae carriage. Therefore, secondary abiotic mice were challenged with MDR-Psae by gavage. One week later, mice were subjected to peroral FMT from either murine or human donors on 3 consecutive days. Irrespective of murine or human origin of fecal transplant, intestinal MDR-Psae loads decreased as early as 24 h after the initial FMT. Remarkably, the murine FMT could lower intestinal MDR-Psae burdens by approximately 4 log orders of magnitude within 1 week. In another intervention study, mice harboring a human gut microbiota were perorally challenged with MDR-Psae and subjected to murine FMT on 3 consecutive days, 1 week later. Strikingly, within 5 days, murine FMT resulted in lower loads and carrier rates of MDR-Psae in mice with a human gut microbiota. In conclusion, FMT might be a promising antibiotics-independent option to combat intestinal MDR-Psae carriage and thus prevent from future endogenous infections of patients at risk.
- Published
- 2019
- Full Text
- View/download PDF